Vericel intends to sell shares of common stock in an underwritten public offering. Proceeds of ~US $17.0MM will support commercialization of MACI® autologous cultured chondrocytes, manufacturing and other general corporate purposes.
FDA approved MACI for the repair of symptomatic single or multiple full-thickness cartilage defects of the knee, with or without bone involvement, in adults. MACI is the first FDA-approved cellularized scaffold that applies tissue engineering processes to grow cells on scaffolds using healthy autologous cartilage tissue.
Vericel intends to sell shares of common stock in an underwritten public offering. Proceeds of ~US $17.0MM will support commercialization of MACI® autologous cultured chondrocytes, manufacturing and other general corporate purposes.
FDA approved MACI for the repair of symptomatic single or multiple full-thickness cartilage defects of the knee,...
Vericel intends to sell shares of common stock in an underwritten public offering. Proceeds of ~US $17.0MM will support commercialization of MACI® autologous cultured chondrocytes, manufacturing and other general corporate purposes.
FDA approved MACI for the repair of symptomatic single or multiple full-thickness cartilage defects of the knee, with or without bone involvement, in adults. MACI is the first FDA-approved cellularized scaffold that applies tissue engineering processes to grow cells on scaffolds using healthy autologous cartilage tissue.
Copy to clipboard 
